Format

Send to

Choose Destination
Clin Neuropharmacol. 2004 May-Jun;27(3):108-10.

Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.

Author information

1
Centre d'Investigation Clinique, Fédération de Neurologie and Inserm, Paris, France.

Abstract

The neuropeptides neurokinin B, neurotensin, and anandamide, the endogenous ligands of NK3, NT1, and CB1 receptors respectively, are known to interact with brain dopaminergic transmission. This study evaluated the effects of these three antagonists of the NK3 (SR 142801), neurotensin (SR 48692), and cannabinoid (SR 141716) receptors on the severity of motor symptoms and levodopa-induced dyskinesias after administration of a single dose of levodopa in 24 patients with Parkinson disease. In this exploratory randomized, double-blind, placebo-controlled study, at the dose used, the drugs tested were well tolerated and could not improve parkinsonian motor disability.

PMID:
15190231
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center